Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness

a technology for respiratory illness and opioids, applied in the direction of drug compositions, biocide, heterocyclic compound active ingredients, etc., can solve the problems of increased carbon dioxide retention, respiratory depression, and morphine-related opioids, and achieve the effect of minimizing the risk of developing sleep

a technology for respiratory illness and opioids, applied in the direction of drug compositions, biocide, heterocyclic compound active ingredients, etc., can solve the problems of increased carbon dioxide retention, respiratory depression, and morphine-related opioids, and achieve the effect of minimizing the risk of developing sleep

US20050053659A1Inactive Publication Date: 2005-03-10QRXPHARMA
9 Cites 16 Cited by

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0060] Effects of Combined Morphine / Oxycodone Formulations on Respiration

[0061] Objective The main objective was to compare the ventilatory responses to hypoxia and hypercarbia following one hour intravenous infusions of (1) morphine 15 mg, or (2) oxycodone 15 mg, or (3) morphine 10 mg+oxycodone 5 mg, or (4) oxycodone 10 mg+morphine 5 mg, or (5) morphine 7.5 mg+oxycodone 7.5 mg. Each infusion was administered over 1 h and was designated by its respective composition as M15, M10_O5, M7.5_O7.5, M5_O10 or O15.

[0062] Design A triple blind placebo-controlled, 5-period, randomised crossover study in 10 males was conducted. On each of the 5 study days for each of the 10 subjects, there was a baseline period, followed by either a 1 h drug or “placebo” i.v. infusion, followed by 1 h “placebo” or drug infusion, followed by a 1 h “washout”. Serial measures of drug effect were accompanied by serial peripheral venous blood sampling. The hypoxemic and hypercapnic ventilatory responses were dete...

example 2

[0066] Analgesia in Patients using Sub-analgesic Combinations of Morphine & Oxycodone in a Ratio of 1:0.66 by Weight

[0067] Objective: to determine the dose of a taste masked oral syrup of morphine and oxycodone in a ratio of 1:0.66 by weight compared to a taste masked syrup containing morphine alone.

[0068] Design A triple-blind (patient, investigator and analyst) randomized, controlled, two-period cross-over study was designed to assess the effectiveness of morphine compared to an oxycodone and morphine mixture. The study was carried out in 21 patients with chronic non-cancer pain. The morphine was formulated to a solution concentration of 5 mg / mL and the combination formulation to a concentration of morphine 1.5 mg / mL and oxycodone 1 mg / mL. The solution strengths were determined so that the expected total dose per day in mL would be similar between the two treatments thereby retaining blinding. Each opioid solution was administered every 4 hours with the 10 pm and 2 am doses bein...

example 3

[0071] Analgesia in Patients using Sub-analgesic Combinations of Morphine & Oxycodeone in a Ratio of 1:2.0 by Weight

[0072] Objective: to determine the dose of a taste masked oral syrup of morphine and oxycodeone in a ratio of 1:2.0 by weight compared to a taste masked syrup containing morphine alone.

[0073] Design & Analysis: a similar design and analysis to that used in Example 1 was followed.

[0074] Results: Analgesic Effects As with Example 2, no significant differences in VAS scores were noted between any of the treatment groups. The effective dose of the 1:2.0 combination versus morphine required to provide analgesia is shown in Table 2. The results show a weight of the combined product to weight or morphine to be 46%. The results was statistically significant (P<0.002).

TABLE 2Comparison of doses required for stabilized pain control.Dose, mgTreatmentPatients(by weight)Morphine2268Combination of2155morphine tooxycodone1:2.0(Morphine +46%Oxycodonedose) / Morphinedose

[0075] In s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to methods for reducing the risk associated with the administration of opioid analgesics in patients diagnosed or undiagnosed with respiratory illness by administering an analgesic composition comprising a sub-analgesic dosage of a μ-opioid agonist selected from the group consisting of morphine, fentanyl, sufentanil, alfentanil, oxymorphone and hydromorphone, or a pharmaceutically acceptable salt thereof, and a sub-analgesic dosage of oxycodone which is a κ2-opioid agonist or a pharmaceutically acceptable salt thereof.

Description

FIELD OF THE INVENTION [0001] The technical field of the invention relates to the use of sub-analgesic doses of opioids for the treatment of pain in patients with a diagnosed or undiagnosed respiratory illness or respiratory disorder. BACKGROUND OF THE INVENTION [0002] When a patient experiences significant pain as the result of a serious traumatic injury, a surgical procedure, or chronic illness (e.g., cancer), relief requires strong medication under a doctor's prescription. Opiate drugs are a class of pain-relieving prescription drugs frequently prescribed for moderate to severe pain. The opioids are a group of drugs, both natural and synthetic, that are employed primarily as centrally-acting analgesics and are opium or morphine-like in their properties (Gilman et al., 1980, GOODMAN AND GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, Chapter 24:494-534, Pergamon Press; hereby incorporated by reference). The opioids include morphine and morphine-like homologs, including, e.g., ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
10 Mar 2005
Publication
US20050053659A1
IPC
A61K9/22; A61K31/445; A61K31/485; A61K45/06; A61P11/00; A61P25/04
CPC
A61K31/445; A61K31/485; A61K45/06; A61K2300/00; A61P11/00; A61P11/06; A61P25/04; A61P25/20
Inventors
PACE, GARY W.; SMITH, MAREE T.